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Purpose. To describe the presence of secretory leukocyte protease inhibitor (SLPI), a cationic peptide with antimicrobial and
antiprotease activity in the innate immune reaction in a rat model of Staphylococcus aureus keratitis. Methods.F o r t yf e m a l e
Lewis rats were divided into 2 groups: the infectious keratitis and the epithelial defect groups. Eyes were processed for
immunohistochemicalstudiesforSLPI,interleukin-1,interleukin-6,tumornecrosisfactor-alpha,andmatrixmetalloproteinase-8.
Results. Immunohistochemical studies conﬁrmed high levels of SLPI, IL-1, IL-6, TNF-α, and MMP-8 expression in eyes with S.
aureus keratitis and with epithelial defects, in contrast to undetectable SLPI expression in the normal control corneas. Conclusions.
Toourknowledge,thispaperistheﬁrsttodemonstratethepresenceofSLPIwithincreasedamountsofproinﬂammatorycytokines
in inﬂamed and infected corneas.
Copyright © 2009 Victor E. Reviglio et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1.Introduction
Infectious keratitis is a sight-threatening complication of
trauma and contact lens wear [1]. Staphylococcus aureus
can cause a virulent suppurative keratitis [2, 3]. Early
diagnosis and prompt treatment are essential to allay the
host inﬂammatory response [3]. Speciﬁc and nonspeciﬁc
defense mechanisms play an important role in ocular
immunity maintaining a delicate balance between eﬀective
defenses and potentially harmful inﬂammation responses
[4]. Antimicrobial peptides contribute to innate immune
defense against a number of Gram-positive and Gram-
negative bacteria, viruses, and fungi [5]. These peptides
include secretory leukocyte protease inhibitor (SLPI) [6–8],
a cationic peptide, as well as defensins and cathelicidins.
Human SLPI is an 11.7 kDa nonglycosylated protein
initially isolated from respiratory mucosal epithelial cells
[8]. It is composed of two domains: a protease inhibitor at
the carboxyl-terminal domain and the antimicrobial amino-
terminal domain [8–10]. SLPI has defensin-like antibacterial
activities and suppresses the production of inﬂammatory
mediators [9]. In a rat model of S.aureus endophthalmitis,
SLPI is present in the inﬂamed vitreous and retina [10].
Recent other studies demonstrate that macrophages secrete
SLPI in response to proinﬂammatory cytokines, bacterial
lipopolysaccharides, and metalloproteinases. We presume
that release of SLPI by inﬂammatory cells in the inﬂamed
cornea may contribute to host defense mechanisms [11].
To determine whether SLPI has a role in primary
infectious keratitis, a condition in which SLPI has not been
described, we investigated and quantiﬁed SLPI expression in
infected and noninfected corneas using a murine model. In
addition, we examined the corneal tissue for the presence of
proinﬂammatory cytokines interleukin 1 (IL-1), interleukin2 Journal of Ophthalmology
6 (IL-6), tumor necrosis factor-alpha (TNF-α), and matrix
metalloproteinase-8 (MMP-8), as important mediators of
corneal wound healing and SLPI expression.
2.MaterialsandMethods
2.1. Experimental Design. Animals were handled in com-
pliance with the tenets of the Association for Research
in Vision and Ophthalmology (ARVO) statement for the
use of animals in Ophthalmic and Vision Research and
the Guide for the Care and Use of Laboratory Animals
(National Research Council). All experiments were approved
by the Institutional Animal Care Committee of the Catholic
University of Cordoba, Argentina.
Forty female Lewis rats, each weighing 250g, were
divided between 2 groups: the S.aureus inoculated group
(20 rats) and the epithelial defect group (20 rats). The left
eyes of both groups served as controls. In the S.aureus
group, 10 rats were assigned to immunohistochemistry and
10 rats to Western blotting at 48 hours. The 20 rats in
the epithelial defect group were divided similarly. The left
c o n t r o le y e sw e r ed i v i d e ds u c ht h a t1 0e y e sw e r ea s s i g n e dt o
immunohistochemistryand10eyeswereassignedtoWestern
blotting.
Wild-type S.aureus from a human endophthalmitis
sample was cultured in tryptase soy broth. The bacterial
suspension was centrifuged and washed with sterile saline.
The suspension was serially diluted with sterile saline to
1.0×108 CFU/mL with optical density of 0.3 at 650nm. The
S.aureus keratitis was induced based on a previous report
[12].
Each rat was anesthetized with an intramuscular injec-
tion of 0.125mL of a 1:1 mixture of 100mg/mL ketamine
and 20mg/mL xylazine; a drop of proparacaine 0.5% was
instilledintherighteyeofbothS.aureusandepithelialdefect
groups. The central 3mm area of the corneal epithelium was
scariﬁed, followed by superﬁcial stroma incision using a 27-
gauge needle.
The S.aureus group received 2 drops, each containing
50uL (1.0 × 108 CFU/mL) of S.aureus suspension, the
epithelial defect group received 50μL of BSS, and the control
group received only one drop of topical proparacaine.
Biomicroscopic examination of the rats was performed 48
hours after inoculation. The rats were then euthanized using
phenobarbital, and the eyes were enucleated for further
study.
2.2. Fixation and Processing of Tissue for Immunohisto-
chemistry. The eyes assigned to immunohistochemical study
were submerged in 10% buﬀered formalin for 3 days,
washed with distilled water, rehydrated through a graded
series of ethanol, embedded in paraﬃn, and processed for
immunohistochemistry.
Immunohistochemical staining was performed using
an avidin-biotin-peroxidase complex technique. Paraﬃn-
embedded sections were treated with 0.6% hydrogen per-
oxide in methanol and blocked with 10% normal goat
serum. Primary antibody consisted of 1:100 dilution of
polyclonal goat anti-SLPI at 1:100 dilution (Santa Cruz
Biotechnology, Inc., Santa Cruz, CA) was applied to the eye
sections, incubated at room temperature for 1 hour, and the
unbound antibody was removed with TBS (20mM Tris-HCl
pH 7.5, 150mM NaCl). A biotinylated rabbit antigoat IgG
secondary antibody (Vector Laboratories, Burlingame, CA)
was applied and ampliﬁed with avidin-biotin-peroxidase
complex (Vector Laboratories). Signals were developed for
visualization with 3, 3  diaminobenzidine. Control sections
were incubated with normal goat serum. All samples were
stained in parallel to minimize specimen variation. Masked
pathologists graded the staining as either present or absent.
2.3. Western Blot Analysis. T h ec e n t r a l4 m mz o n ew a s
trephined from all right and left corneas of all groups. A
3mmsamplewasthenexcisedunderadissectingmicroscope
by a masked pathologist and placed in a sterile tube. The
tissue samples were homogenized separately in phosphate-
buﬀered saline with 100μMb u t y l a t e d - h y d r o x y t o l u e n ea n d
centrifuged for 10 minutes at 15 400g. The supernatants
were stored at –8◦C.
The levels of SLPI, IL-1, IL-6, TNF-α,a n dM M P - 8f r o m
corneas were assessed by Western blot, with each blot being
performed in duplicate. The blot was probed with puriﬁed
goat polyclonal antibody from Santa Cruz Biotechnology,
Inc.. For the positive control we used serum from rats with
S.aureus sepsis (data not shown). Fifteen microliters of each
homogenate were run under either reducing or nonreducing
(r, nr) conditions at ambient temperature using a modiﬁed
Laemmli method. The samples were electrophoresed on 10–
15% polyacrylamide SDS gel at 100volts for 2 hours and
transferred to nitrocellulose membranes at 120volts for 2
hours (Bio-Rad, Richmond, CA). The nitrocellulose paper
was incubated at room temperature in blocking buﬀer (PBS,
0.05% Tween 20, 0.5% nonfat dry milk), with the primary
antibody (dilution range 1:100–1:1000) and the secondary
antibody (dilution range 1:1000–1:2000) for 1 hour each
on a rotating platform. After three washes with TBS-T
(TBS, 0.05% Tween-20), the membranes were incubated
in enhanced chemilluminescence solution (Amersham Life
Science, Arlington Heights, IL) followed by exposure to ﬁlm.
The values of bands from Western blots of the S.aureus,
epithelial defect, and control groups were quantiﬁed using
a software program for densitometric analysis (Molecular
Dynamics, Sunnyvale, CA) and normalized to a standard
curve to obtain relative SLPI values.
2.4. Statistical Analysis. Immunoreactivity was reported as
the ratio of eyes positive for SLPI immunostaining to the
total number of eyes. The ratio was compared to that of
the control group. A P-value less than .05 was considered
statistically signiﬁcant (Fisher exact test).
T h em e a nd e n s i t o m e t r yv a l u e sf r o mW e s t e r nb l o t sw e r e
subjected to statistical analysis to determine whether there
was a diﬀerence between the S.aureus and the epithelial
defect groups as compared to the control eyes. A P-value
less than .05 was considered statistically signiﬁcant (Mann-
Whitney test).Journal of Ophthalmology 3
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(a) cornea infected with S.aureus displays
increased SLPI immunoreactivity and neutro-
philic inﬁltration in the epithelium (arrowheads)
and stroma (asterisks) (800× magniﬁcation)
∗
∗
∗ ∧ ∧ ∧
(b) cornea with epithelial defect displays some
positively staining cells in the epithelium (arrow-
heads) and stroma (asterisks) (400× magniﬁca-
tion)
(c) control cornea does not display immunos-
taining (400× magniﬁcation)
Figure 1: Immunolocalization of SLPI at 48 hours in corneas with S.aureus keratitis, epithelial defect, and control.
3. Results
We used a murine model to help elucidate the role of SLPI,
an antimicrobial peptide, in inﬂammatory and infectious
keratitis. Forty-eight hours postinoculation, eyes from the
S.aureus inoculated group demonstrated an intense inﬂam-
matory reaction at slit lamp examination. Immunohisto-
chemical studies of the S.aureus eyes showed a neutrophilic
inﬁltrate consistent with the inﬂammatory response seen
on histopathologic examination. There was intense staining
of SLPI localized in the eye structures compromised by
inﬂammation; positive staining for SLPI in the corneal
epithelium and stroma corroborated the slit lamp ﬁndings
of keratitis (Figure 1(a)).
Corneas in the epithelial defect group displayed defects
measuring less than 1mm at 48 hours on slit lamp examina-
tion. SLPI expression was found mainly at the levels of the
corneal epithelium and anterior stroma beneath the wound,
and it was associated with a weak level of neutrophilic
inﬁltration (Figure 1(b)) .T h ee y e sf r o mt h ec o n t r o lg r o u p s
didnotdemonstrateclinicalsignsofinﬂammation;therewas
no inﬂammatory cell inﬁltrate or SLPI immunostaining of
the cornea (Figure 1(c)).
Protein levels were measured by Western blot analysis
from diﬀerent groups. Similarly, immunoblots displayed a
high level of SLPI expression in the S.aureus group. It was
consistently observed that a lower level of expression was
present in the epithelial defect group followed by the normal
control group (Figure 2).
As we are interested in the relationship amongst SLPI
expression, neutrophil recruitment, and corneal wound
healing, we examined the three experimental groups for
expression of proinﬂammatory cytokines IL-1, IL-6 and
TNF-α, and MMP-8. Proinﬂammatory cytokines and MMP-
8( Figure 3) were detectable in both S.aureus and epithelial
defect groups at 48 hours by Western blot technique.
However, the S.aureus group showed a much higher level
of expression of all proinﬂammatory cytokines and MMP-8
compared to either epithelial defect or control groups when
the bands from the Western blot were quantiﬁed (Figure 4).
The diﬀerences between S.aureus versus the control group
123 45 6 7
(a) Lanes 1-2 represent control corneas; lanes 3-4 and 6-7
show a high level of expression of SLPI in the S.aureus keratitis
group. Lane 5 is a molecular weight marker at 12 kDa
123 45 6 7
(b) Lanes 1–3 represent control corneas, and lanes 5–7 are the
epithelial defect group. Lane 4 is the molecular weight marker.
Bands are representative of duplicate experiments with similar
results
Figure 2: Representative Western blots of SLPI expression of
supernatant samples from the S.aureus, the epithelial defect, and
control groups of rat corneas.
and the epithelial defect group versus the control group were
statistically signiﬁcant (
∗P <. 05).
4. Discussion
Previously, we hypothesized that SLPI plays a role in the
innate immune defense of the eye in response to intraocular
inﬂammationandinfection. ThisstudydocumentsthatSLPI
is strongly expressed in a murine model of S.aureus keratitis,
that SLPI expression is directly associated with inﬁltration by
inﬂammatory cells in these corneas, and to our knowledge, is
the ﬁrst to document an association between expressions of
SLPI and proinﬂammatory cytokines. Given what is known
about the role of SLPI in other tissues such as lung, skin,
and placenta [8, 13, 14] and our previous study of SLPI
in a murine model of S.aureus endophthalmitis [10], our
ﬁndings further support that SLPI is secreted in order to
promote the early eradication of invading microorganisms
and to protect the eye against proteolytic destruction by
inﬂammatory cells. The correlation of expression of SLPI in4 Journal of Ophthalmology
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Figure 3: Expression of SLPI, IL-1, IL-6, TNF-α, and MMP-8 in S.aureus, epithelial defect, and control groups. After 48 hours, corneas were
dissected and homogenized, and protein levels were examined by Western blot. Bands represent duplicate experiments with similar results.
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Figure 4: Comparison of S.aureus, epithelial defect, and control
corneas in terms of quantiﬁed expression of SLPI, proinﬂammatory
cytokines, and MMP-8 from Western blots. The results shown
are the mean ± SD. Diﬀerences between values are statistically
signiﬁcant (
∗P <. 05 compared with untreated control).
location, time, and intensity with the primarily neutrophilic
inﬂammatory process and with the expression of proin-
ﬂammatory cytokines strongly supports that expression of
SLPI is upregulated as a result of increased expression of
proinﬂammatory cytokines.
We conclude that corneal inﬂammation and infection
lead to SLPI expression based on the presence of elevated
SLPI expression in S.aureus -infected and epithelial defect
eyes, but not in normal control eyes. Furthermore, SLPI
and proinﬂammatory cytokines were induced in the early
stage of corneal wound healing in the epithelial defect group,
but were expressed at lower levels compared to the levels
in the S.aureus group. This suggests that neutrophils play
a role in maintaining a high level of SLPI in the infected
corneas.
Corneal wound healing after injury involves a complex
cascade of events involving cytokine-mediated interactions
amongst the epithelial cells, activated keratocytes of the
corneal stroma, components of the tear ﬁlm, and cells of the
immune system [12, 15]. These cytokines are multipotential
proteins, playing an essential role during corneal wound
healing, and they are upregulated after injury initiating the
cascade of events that constitute the corneal wound healing
[12, 15, 16]. Our particular interests are IL-1, IL-6, and TNF-
alpha, as levels of these are signiﬁcantly upregulated after
corneal injury and correlated with the severity of damage
[2, 3, 12, 17].
The concept that certain peptides have anti-inﬂamma-
tory properties and contribute to the innate host defense
has been reported in other organ systems [18]. Speciﬁ-
cally, SLPI is involved in protection against damage from
tissue inﬂammation [9, 12]. It also neutralizes the action
of neutrophil elastase as well as other metalloproteinases
secreted in the ECM [13, 19, 20]. The interactions of MMPs
with speciﬁc inhibitors as well as with prostaglandins and
cytokines are essential for the regulation of normal corneal
wound healing [4, 15, 16, 21]. Taken together with reports
that MMP-8 is present in neutrophil granules (and is also
known as neutrophil collagenase), it is highly likely that
neutrophils are the major source of the metalloproteinase
in the current study [16]. In addition, SLPI is upregulated
in response to proinﬂammatory cytokines and to bacterial
products[9,11].PreviousexperimentsshowSLPIexpression
inbronchial,nasal,andcervicaltissues,intears,andinocular
tissue [19, 21]. Our study expands upon these ﬁndings and
highlights the role of SLPI in intraocular inﬂammation and
ocular innate immunity.
Recent studies, including a murine model of endoph-
thalmitis, demonstrate that the SLPI is secreted by inﬂam-
matory and noninﬂammatory cells in response to tissue
destruction [8, 9, 12, 14, 22, 23]. In conjunction with our
ﬁndings, SLPI likely plays a similarly important pathophys-
iologic role in S.aureus keratitis. Most likely, it is expressed
in response to inﬂammation itself, although our data do
not directly rule out SLPI expression directly induced by
bacterial toxins or cell wall components. In our experiments,
increased expression of SLPI was found not just in associ-
ation with neutrophilic inﬁltration, but also with increased
cytokine production. As in other organ systems, expression
of SLPI may be upregulated in response to proinﬂammatory
cytokines [8, 13].Journal of Ophthalmology 5
5. Conclusion
We demonstrate that SLPI may be secreted in order to
promote the early eradication of invading microorganisms
and to protect the cornea against proteolytic destruction
by inﬂammatory cells. The known antiprotease and antimi-
crobial activities of SLPI suggest that its expression is
actively regulated at the site of ocular tissue inﬂammation.
In addition to supportive ﬁndings in other organ systems,
our study suggests that expression of SLPI may be up
regulated as a result of increased expression of IL-1, IL-
6, TNF-alpha, and MMP-8. Expression of SLPI may have
a role in regulation of neutrophil recruitment. Because
of its endogenous antimicrobial activities and role as an
inﬂammatory mediator, further studies addressing the role
of SLPI in innate ocular immunity and in wound-healing
may have consequences in the development of innovative
prophylactic and therapeutic strategies for eye disease.
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